US2013203805A1PendingUtilityA1

Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase

63
Assignee: KLAUS STEPHEN JPriority: Dec 6, 2001Filed: Sep 13, 2012Published: Aug 8, 2013
Est. expiryDec 6, 2021(expired)· nominal 20-yr term from priority
Inventors:Stephen J. KlausAl Y. LinThomas B. NeffQingjian WangVolkmar Guenzler-PukallMichael P. ArendLee A. FlippinAlex Melekhov
A61P 37/04A61P 3/10A61P 9/10A61P 7/06A61P 37/00A61P 9/00A61P 9/04A61P 39/00A61P 9/12A61P 43/00A61P 9/08A61P 7/00A61P 25/00A61P 25/16A61P 29/00A61P 25/14A61P 35/00A61P 31/00A61P 25/28A61P 25/08A61P 1/04A61P 17/02A61P 13/12A61P 1/16A61P 11/00A61K 31/4738A61K 31/17C07K 14/505A61K 31/47A61K 31/4418A61K 38/1709A61K 31/496A61K 31/44G01N 33/746A61K 31/472A61K 31/4745C07K 14/4702A61K 31/4375A61K 31/63A61K 31/00
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating anemia in a subject, the method comprising administering to the subject an effective amount of a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase. 
     
     
         2 . The method of  claim 1 , wherein the subject is a subject having chronic kidney disease. 
     
     
         3 . The method of  claim 1 , wherein the compound is selected from the group consisting of a heterocyclic carboxamide, a phenanthroline, and a hydroxamate. 
     
     
         4 . The method of  claim 1 , wherein the compound is a heterocyclic carboxamide. 
     
     
         5 . The method of  claim 1 , wherein the subject is undergoing or is at risk for undergoing kidney dialysis. 
     
     
         6 . The method of  claim 1 , wherein the compound is delivered orally. 
     
     
         7 . The method of  claim 2 , wherein the subject is undergoing or is at risk for undergoing kidney dialysis.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.